| Document and Entity Information - USD ($) | 12 Months Ended | ||
| Dec. 31, 2023 | Mar. 22, 2024 | Jun. 30, 2023 | |
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Entity Interactive Data Current | Yes | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction | false | ||
| Amendment Flag | true | ||
| Amendment Description | AN2 Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Original Filing”), which was originally filed with the Securities and Exchange Commission on March 29, 2024, solely for the purpose of filing revised versions of Exhibits 31.1 and 31.2 filed with the Original Filing. Revised Exhibits 31.1 and 31.2 include the following certification language that was inadvertently omitted from such exhibits when originally filed: (i) the introductory language in paragraph 4 that refers to the certifying officer’s responsibility for establishing and maintaining internal control over financial reporting for the Company; and (ii) paragraph 4(b) regarding the design of internal control over financial reporting. This Amendment does not reflect events occurring after the date of the filing of the Original Filing or modify or update any of the other disclosures contained therein in any way. Accordingly, the Amendment should be read in conjunction with the Original Filing. This Amendment consists solely of the preceding cover page, this explanatory note, the signature page and the revised certifications filed as exhibits to this Amendment. | ||
| Document Period End Date | Dec. 31, 2023 | ||
| Document Fiscal Year Focus | 2023 | ||
| Document Fiscal Period Focus | FY | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Registrant Name | AN2 Therapeutics, Inc. | ||
| Entity Central Index Key | 0001880438 | ||
| Entity File Number | 001-41331 | ||
| Entity Tax Identification Number | 82-0606654 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Current Reporting Status | Yes | ||
| Entity Shell Company | false | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Ex Transition Period | false | ||
| Entity Address, Address Line One | 1800 El Camino Real | ||
| Entity Address, Address Line Two | Suite D | ||
| Entity Address, City or Town | Menlo Park | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 94027 | ||
| City Area Code | 650 | ||
| Local Phone Number | 331-9090 | ||
| Title of 12(b) Security | Common Stock | ||
| Trading Symbol | ANTX | ||
| Security Exchange Name | NASDAQ | ||
| Entity Common Stock, Shares Outstanding | 29,770,375 | ||
| Entity Public Float | $ 108,668,174 |
